Despite the growing number of users reporting benefits of microdosing (mostly psilocybin or LSD) for depression and other mood disorders, no rigorous study investigating these claims has ever been conducted to date.

Our new collaborator, Prof Harriet de Wit from the University Of Chicago, who has already conducted some of the earliest laboratory-based studies on LSD microdosing, is currently undertaking a study in individuals with high levels of depression in order to explore more specifically the therapeutic potential of LSD microdosing for the treatment of this condition.

Peer-reviewed articles

Media articles

 

We cannot advise on the procurement of illegal psychoactive substances, nor can we recommend self-medication. While we and other advocacy groups are working for psychedelics to become accepted into medical practice, we also acknowledge that – especially outside of the context of a controlled environment under the supervision of trained professionals – they can have serious and traumatic consequences.

A growing community of psychiatrists and therapists can offer support for those seeking help in making sense of psychedelic experiences. These include those listed at Psychedelic.Support and the MAPS Integration List.

 

.